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Labial fusion is a rare form of female genital chronic graft-
versus-host disease (GvHD). We report on the successful
treatment of ﬁve patients who presented with labial fusion
between 23 months and 8 years post-hematopoietic cell
transplantation (HCT) (Table). Of these ﬁve women, three
had severe sclerotic GvHD (Patient 1, 3, 4), one woman had
bronchiolitis obliterans (Patient 2), and one woman had no
other GvHD sites (Patient 5). In all cases, labial fusion was
classiﬁed as severe vulvovaginal GvHD (Stratton-TurnerTable.
Patient Underlying disease/
indication for transplant
Conditioning regimen; GvHD proph
at the time of genitalGvHD diagnos
1 Hodgkin lymphoma
then MDS
Unknown; sirolimus, and steroids
2 AML BuCy2 conditioning; no GVHD prop
3 Ewing sarcoma then AML Cy/TBI conditioning; tacrolimus,cell
prednisone
4 myeloﬁbrosis Fludarabine/busulfan conditioning;
tacrolimus, prednisone,pomalidami
5 Sickle cell anemia 300 rads TBI, alemtuzumab;sirolimuGrade III). Patient 1 presented with worsening difﬁculty
with micturition, vulvar fullness and inability to have in-
tercourse; she had only a pinpoint opening for passage of
urine. Severe sclerotic GvHD also signiﬁcantly narrowed her
mouth opening. Her complete labial fusion and vaginal ad-
hesions were lysed under general anesthesia. Three of ﬁve
women (Patient 2, 3, 4) presented with dyspareunia. The
remaining woman (Patient 5) was not sexually active; labial
fusion was noted during routine gynecology examination.
The labia of these four women were fused between the
clitoris and urethra resulting in a narrowed vaginal opening
without urethral obstruction. Their labial adhesions were
successfully lysed during an ofﬁce procedure using local
anesthesia. In all patients, topical skin adhesive (derma-
bond) was applied to the denuded labial surfaces to main-
tain labial separation during healing. Once the labial mucosa
healed, patients applied topical clobetasol ointment and
topical estrogen to the affected area for several weeks to
prevent reagglutination. On follow-up, all women were
signiﬁcantly improved and dyspareunia resolved. These
patient histories highlight the importance of asking women,
especially those with severe chronic GvHD, about dyspar-
eunia and pain with urination. Those with genital symptoms
warrant referral to a gynecologist skilled in evaluation and
treatment of women post-HCT. These cases illustrate that
labial fusion from chronic GvHD, if diagnosed early enough,
may be treated successfully with an ofﬁce procedure and
medical therapy.ylaxis
is
Time point
post-HCT
Other sites of GvHD Symptoms of
genital GvHD
8 years sclerotic skin, eyes,
mouth, esophageal
strictures
inability to have
intercourse
hylaxis 2 yr 4 mo BOS dyspareunia
cept, 1 yr 11 mo sclerotic skin dyspareunia
de
5 yr 9 mo sclerotic skin, eyes,
mouth, joint and gyn
dyspareunia
s 4 yrs none none
